HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
AIM ImmunoTech Announces Authorizations From Competent Authority And Ethics Board In The Netherlands To Begin A Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca’s Imfinzi For The Treatment Of Pancreatic Can
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy
Patient enrollment expected to commence before the end of 2023
OCALA, Fla., June 27, 2023 (GLOBE
